Teva moving away from major acquisitions

Teva chairman Phillip Frost told "Bloomberg" that the pharmaceutical company is changing its acquisition strategy.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) chairman Phillip Frost told "Bloomberg" that the pharmaceutical company is changing its strategy and moving away from multi-billion dollar acquisitions.

He said, Acquisitions dont have to be major to be important. The idea of the multibillion-dollar type of acquisition is going to be reserved for very special cases going forward, in which the desirability is so compelling and so game-changing that everyone will feel it has to be done.

Frost owns about $815 million of Teva shares.

He said, There is the opportunity for product acquisitions, for small company acquisitions, for technology acquisitions, and to bring in new people who themselves are capable of creating the new products."

Over the past decade alone, Teva has made 25 acquisitions including five of more than $3 billion each.

Speaking about Teva's new CEO, Frost said, On the novel product side, Jeremy brings experience to the table that we didnt really have at Teva before."

On Multiple Sclerosis treatment Copaxone he said, Copaxone will be around for quite a while - Im sure of it. At a certain point, its possible a generic will affect certain markets, but the product itself will continue to be important in other markets.

Meanwhile, Teva CEO Jeremy Levin paid a visit to a Teva plant in Ashdod, which has come under heavy rocket fire from the Gaza Strip in the past week. "These men and women are the embodiment of Tevas values, making the medicines we send abroad even in the most difficult of times and ensuring we keep our commitment to patients worldwide. These employees make the medicines that cross borders - even across Israels most immediate border - in order to uphold Tevas covenant with patients around the world," Levin wrote in a letter to Teva employees worldwide following the visit, during which sirens warning of incoming rockets sounded several times.

Published by Globes [online], Israel business news - www.globes-online.com - on November 21, 2012

Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments

 
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters